Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
ICON Public Limited Company logo

NASDAQ · ICLR

ICON Public Limited Company

Healthcare · Medical - Diagnostics & Research

$215.48

Down-$4.12 (-1.91%)

Updated Oct 31, 2026, 1:52 AM

SID Score

7.8/10

Composite research score

Smart Money

56/100

Neutral

Market cap
14.49B
P/E ratio
24.5
Dividend yield
0.00%
52-week range
$66.57 – $219.04
Volume
1.8M
Avg. volume
993.9K

Price performance · ICLR

ICLR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

ICLR closed at $215.48 after 20 trading sessions, up 32.97% for the selected period.

Last close
$215.48
Period change
+32.97%
Period low
$161.69
Period high
$215.48
Daily close
View OHLC price history
ICLR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$211.53$219.04$207.535$215.481.8M
Oct 28, 2026$199.19$214.94$195.80$214.163.95M
Oct 27, 2026$182.23$186.99$181.735$182.98890.73K
Oct 26, 2026$182.08$185.59$179.16$183.781.07M
Oct 23, 2026$184.25$185.57$179.89$185.271.02M
Oct 22, 2026$180.09$190.56$180.09$185.431.02M
Oct 21, 2026$171.54$188.27$171.54$185.251.16M
Oct 20, 2026$169.26$176.725$168.64$174.19936.27K
Oct 19, 2026$169.25$173.1083$167.14$168.14728.53K
Oct 16, 2026$173.58$176.81$167.945$170.18667.94K
Oct 15, 2026$170.20$177.195$166.94$175.13795.83K
Oct 14, 2026$163.54$170.32$163.14$168.97629.66K
Oct 13, 2026$164.54$166.17$159.715$164.34816.54K
Oct 12, 2026$165.14$169.83$163.90$164.40869.55K
Oct 9, 2026$167.04$169.85$163.47$164.17745.64K
Oct 8, 2026$161.62$164.95$159.155$164.501.03M
Oct 7, 2026$160.93$165.22$157.375$164.08776.24K
Oct 6, 2026$169.69$177.67$161.14$161.69984.01K
Oct 5, 2026$161.07$168.76$160.985$168.33932.55K
Oct 2, 2026$161.85$163.43$160.41$162.05676.14K

Latest ICLR news

The latest Smart Investors Daily articles mentioning ICLR.

Stock researchCompany · Overview

ICLR research

Overview

Company profile and research snapshot.

Company profile

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$205.00
Implied upside
—
Analysts
24
ICLR recent ratings
DateFirmRatingTarget
Oct 29, 2026BairdOutperform—
Oct 29, 2026RBC CapitalOutperform—
Oct 29, 2026Truist SecuritiesBuy—
Oct 29, 2026BarclaysEqual-Weight—
Oct 29, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

ICON (ICLR) Stock Could Be A Bargain After Cash Flow Rebound

ICON shares have climbed back to US$185.25 after a choppy few years, so the live question is whether that rebound is supported by the cash the business is expected to generate. With mixed recent returns and evolving expectations for future work, investors are weighing how the current price lines up with the intrinsic value suggested by its Discounted Cash Flow (DCF) model. Over the past 5 years the stock has fallen 34.2%, which puts the focus squarely on whether future cash flows can justify...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By